AVROBIO Inc. (AVRO) Financial Statements (2024 and earlier)
Company Profile
Business Address |
490 ARSENAL WAY WATERTOWN, MA 02472 |
State of Incorp. | DE |
Fiscal Year End | December 31 |
Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | |||
---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||
Current Assets | |||||||||
Cash, cash equivalents, and short-term investments | 90,481 | 98,020 | 105,842 | 124,689 | 72,326 | 92,563 | |||
Cash and cash equivalents | 90,481 | 98,020 | 105,842 | 124,689 | 72,326 | 92,563 | |||
Restricted cash and investments | 283 | 283 | 283 | 283 | 283 | ||||
Prepaid expense | 411 | 816 | 1,221 | 32 | 515 | 999 | |||
Asset, held-for-sale, not part of disposal group | 185 | ||||||||
Other current assets | 626 | 570 | 805 | 792 | 845 | 1,008 | |||
Other undisclosed current assets | 37 | 572 | 834 | 3,047 | 3,565 | 5,105 | |||
Total current assets: | 91,838 | 100,261 | 109,170 | 128,843 | 77,251 | 99,958 | |||
Noncurrent Assets | |||||||||
Finance lease, right-of-use asset, after accumulated amortization | |||||||||
Operating lease, right-of-use asset | 110 | 432 | 912 | 2,267 | 2,857 | 1,057 | |||
Property, plant and equipment | 2,285 | 2,285 | 2,285 | 2,574 | 2,894 | ||||
Restricted cash and investments | 400 | 400 | 400 | 400 | 283 | ||||
Other noncurrent assets | 40 | 40 | 40 | 40 | |||||
Other undisclosed noncurrent assets | (2,285) | (2,285) | |||||||
Total noncurrent assets: | 510 | 832 | 1,352 | 4,992 | 5,754 | 3,991 | |||
TOTAL ASSETS: | 92,348 | 101,093 | 110,522 | 133,835 | 83,005 | 103,949 | |||
LIABILITIES AND EQUITY | |||||||||
Liabilities | |||||||||
Current Liabilities | |||||||||
Accounts payable and accrued liabilities, including: | 3,285 | 5,476 | 5,912 | 9,414 | 11,672 | 12,116 | |||
Accounts payable | 243 | 27 | 910 | 1,071 | 591 | 384 | |||
Accrued liabilities | 3,042 | 5,449 | 5,002 | 8,343 | 11,081 | 11,732 | |||
Other undisclosed accounts payable and accrued liabilities | |||||||||
Debt | |||||||||
Other undisclosed current liabilities | 224 | 878 | 1,647 | 2,250 | 2,627 | 999 | |||
Total current liabilities: | 3,509 | 6,354 | 7,559 | 11,664 | 14,299 | 13,115 | |||
Noncurrent Liabilities | |||||||||
Long-term debt and lease obligation | 15,356 | 15,276 | |||||||
Long-term debt, excluding current maturities | 15,356 | 15,276 | |||||||
Finance lease, liability | |||||||||
Liabilities, other than long-term debt | 105 | 134 | 352 | 188 | |||||
Operating lease, liability | 105 | 134 | 352 | 188 | |||||
Total noncurrent liabilities: | 105 | 134 | 15,708 | 15,464 | |||||
Total liabilities: | 3,509 | 6,354 | 7,664 | 11,798 | 30,007 | 28,579 | |||
Equity | |||||||||
Equity, attributable to parent | 88,839 | 94,739 | 102,858 | 122,037 | 52,998 | 75,370 | |||
Common stock | 4 | 4 | 4 | 4 | 4 | 4 | |||
Additional paid in capital | 572,918 | 572,010 | 571,344 | 568,946 | 567,383 | 564,798 | |||
Accumulated other comprehensive loss | |||||||||
Accumulated deficit | (484,083) | (477,275) | (468,490) | (446,913) | (514,389) | (489,432) | |||
Total equity: | 88,839 | 94,739 | 102,858 | 122,037 | 52,998 | 75,370 | |||
TOTAL LIABILITIES AND EQUITY: | 92,348 | 101,093 | 110,522 | 133,835 | 83,005 | 103,949 |
Income Statement (P&L) ($ in thousands)Annual | Quarterly
6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | ||
---|---|---|---|---|---|---|---|---|
Revenues | 77 | 23 | 23 | 23 | 23 | |||
Sublease income | 23 | 23 | 23 | |||||
Gross profit: | 23 | 23 | 23 | |||||
Operating expenses | (7,941) | (9,627) | (21,091) | (15,729) | (25,220) | (25,257) | ||
Other undisclosed operating income (loss) | (35) | (1,865) | 83,713 | (23) | ||||
Operating income (loss): | (7,941) | (9,662) | (22,933) | 68,007 | (25,220) | (25,257) | ||
Nonoperating income (expense) | 1,133 | 1,254 | 1,356 | (531) | 263 | 223 | ||
Investment income, nonoperating | 1,146 | 1,260 | 1,407 | (495) | 248 | 245 | ||
Interest and debt expense | 1,003 | (1,367) | (803) | |||||
Other undisclosed loss from continuing operations before equity method investments, income taxes | (1,861) | |||||||
Income (loss) from continuing operations before income taxes: | (6,808) | (7,405) | (21,577) | 66,109 | (25,760) | (26,895) | ||
Other undisclosed loss from continuing operations | (377) | |||||||
Income (loss) from continuing operations: | (6,808) | (7,782) | (21,577) | 66,109 | (25,760) | (26,895) | ||
Other undisclosed net income (loss) | (1,003) | 803 | 1,861 | |||||
Net income (loss): | (6,808) | (8,785) | (21,577) | 66,109 | (24,957) | (25,034) | ||
Other undisclosed net income attributable to parent | 1,367 | |||||||
Net income (loss) available to common stockholders, diluted: | (6,808) | (8,785) | (21,577) | 67,476 | (24,957) | (25,034) |
Comprehensive Income ($ in thousands)Annual | Quarterly
6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | ||
---|---|---|---|---|---|---|---|---|
Net income (loss): | (6,808) | (8,785) | (21,577) | 66,109 | (24,957) | (25,034) | ||
Other comprehensive loss | ||||||||
Comprehensive income (loss), net of tax, attributable to parent: | (6,808) | (8,785) | (21,577) | 66,109 | (24,957) | (25,034) |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.